{"id":"obv-ptv-r-and-dsv","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Elevated bilirubin"}]},"_chembl":{"chemblId":"CHEMBL446926","moleculeType":"Small molecule","molecularWeight":"889.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets three essential HCV non-structural proteins to prevent viral RNA replication and protein processing. OBV (ombitasvir) inhibits NS5A, PTV (paritaprevir) with ritonavir (r) boosts protease inhibition of NS3/4A, and DSV (dasabuvir) inhibits NS5B polymerase. The triple mechanism provides high barrier to resistance and achieves sustained virologic response in HCV genotype 1 patients.","oneSentence":"OBV/PTV/r and DSV is a fixed-dose combination of hepatitis C virus (HCV) NS5A inhibitor, NS3/4A protease inhibitor, and NS5B nucleotide polymerase inhibitor that blocks viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:58.882Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) genotype 1 infection"}]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":"HCV Coinfection","enrollment":7},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Viekirax and Exviera"],"phase":"marketed","status":"active","brandName":"OBV/PTV/r and DSV","genericName":"OBV/PTV/r and DSV","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OBV/PTV/r and DSV is a fixed-dose combination of hepatitis C virus (HCV) NS5A inhibitor, NS3/4A protease inhibitor, and NS5B nucleotide polymerase inhibitor that blocks viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}